Symlin
Evidence Grade A — Regulatory approved. 442 published studies. 59 registered clinical trials.
Loading...
Pramlintide (sold as Symlin) is an injectable medication that replaces amylin — a hormone your pancreas normally releases alongside insulin after every meal. In people with diabetes (especially type 1), amylin production is reduced or absent. Pramlintide fills this gap by slowing digestion, reducing appetite, and preventing inappropriate blood sugar spikes after eating. It is the only approved amylin-based treatment.
442 published studies: 350 human, 28 animal, 23 in-vitro, 172 reviews
Pramlintide is marketed as Symlin (approved March 2005) and remains the only approved amylin-based treatment. It is used alongside mealtime insulin in both type 1 and type 2 diabetes. Clinical trials showed modest blood sugar improvements (HbA1c reductions of 0.2–0.6%) and approximately 2.3 kg of weight loss — less dramatic than GLP-1 treatments but meaningful as an add-on therapy.
Symlin carries a boxed warning for severe hypoglycaemia, particularly when combined with insulin, and requires careful dose adjustment. Practical uptake has been limited by the need for separate injections at each meal alongside existing insulin injections. Despite its modest clinical impact, pramlintide remains the only medication that addresses the amylin deficiency in diabetes, filling a distinct biological role that GLP-1 treatments do not cover.
Every time your pancreas releases insulin after a meal, it also releases a companion hormone called amylin. In people with diabetes, amylin production is reduced or absent (especially in type 1 diabetes). Pramlintide replaces this missing hormone. It slows stomach emptying so food is absorbed more gradually, tells the brain you are full to reduce overeating, and suppresses the inappropriate release of glucagon (a hormone that raises blood sugar) after meals. These three effects work alongside insulin to smooth out the blood sugar spikes that follow eating.
Clinical trials showed modest blood sugar improvements (HbA1c reductions of 0.2-0.6%) and approximately 2.3 kg of weight loss when added to insulin therapy. These results are less dramatic than GLP-1 medications, and the requirement for additional injections at every meal — on top of existing insulin injections — has been a major practical barrier. Symlin carries a boxed warning for severe hypoglycaemia when combined with insulin, requiring careful dose adjustment. Despite its limited commercial success, the amylin pathway is now experiencing a resurgence of interest. Cagrilintide, a next-generation long-acting amylin analogue from Novo Nordisk, is being studied in combination with semaglutide (as CagriSema) — a combination that could potentially validate the amylin approach in a way pramlintide's inconvenient dosing never could.
Pancreatic Polypeptide as a Modulator of Amylin- Induced Satiety in Healthy Humans
Hypersensitivity to Amylin in Post-Traumatic Headache
Amylin-Induced Migraine Attacks Without Aura
Two Way Crossover Closed Loop Study Insulin vs Insulin and Pramlintide
The Role of Amylin in Bone Metabolism
FDA ORIG 1
FDA SUPPL 6
FDA SUPPL 10
FDA SUPPL 20
FDA SUPPL 7
FDA SUPPL 16
FDA SUPPL 23
FDA SUPPL 25
FDA SUPPL 24
FDA SUPPL 26
FDA SUPPL 28
Exenatide was the first GLP-1 receptor agonist approved anywhere, reaching the market as Byetta in April 2005. The once-weekly formulation Bydureon followed in 2012. Clinical trials showed blood sugar reductions (HbA1c) of 1.6–1.9% and modest weight loss of 2–4 kg. The EXSCEL cardiovascular outcomes trial, involving over 14,700 patients, showed a trend toward cardiovascular benefit but narrowly missed statistical significance. While exenatide was groundbreaking as the first in its class, it has been largely overtaken by newer GLP-1 treatments that offer greater efficacy, less frequent dosing, and proven cardiovascular benefits. It remains available and in clinical use, particularly in combination products.
Lixisenatide was marketed as Adlyxin in the US (approved July 2016), though it has since been discontinued in the US market. The ELIXA cardiovascular trial, involving over 6,000 patients, was the first cardiovascular outcomes trial for any GLP-1 medication to report results. It showed a neutral cardiovascular profile — neither harmful nor beneficial — meeting safety requirements but not demonstrating the heart benefits later shown by semaglutide and liraglutide. Lixisenatide found its primary clinical role in combination with basal insulin, marketed as Soliqua (lixisenatide plus insulin glargine). This combination addresses both fasting blood sugar (via insulin) and post-meal spikes (via lixisenatide) in a single daily injection. As a standalone treatment, it has been largely superseded by more potent GLP-1 medications.
Octreotide is marketed as Sandostatin (approved 1988), Sandostatin LAR monthly depot (approved 1998), and Mycapssa oral capsules (approved June 2020 — the first oral somatostatin analogue). It is used for acromegaly, carcinoid syndrome, VIPomas, and gastroenteropancreatic neuroendocrine tumours (GEP-NETs). The PROMID trial demonstrated that octreotide LAR significantly delayed tumour progression in patients with neuroendocrine tumours of the midgut, establishing somatostatin analogues as a standard treatment for these cancers. The approval of Mycapssa as an oral formulation was a significant advance for patients who had been receiving monthly injections for years. Octreotide has been on the market for over 35 years and has one of the longest safety track records of any peptide medication.
